Autolus Therapeutics plc announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc. The agreement allows Cabaletta to incorporate Autolus' proprietary RQR8 safety switch(1) into a cell therapy program for the treatment of autoimmune disease, with an option for Cabaletta to incorporate the safety switch in up to four additional cell therapy programs. Under the terms of the agreement, Autolus will receive an upfront payment for non-exclusive access to the RQR8 safety switch for use in Cabaletta's CD19-CAR T cell therapy program for the treatment of autoimmune disease, with the potential for near term option exercise fees and development and regulatory milestone payments. In addition, Autolus is entitled to receive royalties on net sales of all Cabaletta cell therapy products that incorporate the RQR8 safety switch. This agreement demonstrates how Autolus is able to generate value from its technologies and pipeline and follows similar deals with Bristol Myers Squibb and Moderna.